EcoR1 Capital, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001587114

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 34 positions · Total reported value $2.11B · Top-10 concentration 84.4% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 47.5% · 9 new · 4 cut · 6 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -3.0% · vs SPY -5.1% · Prev Value $1.95B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +0.9% · vs SPY -1.2% · Latest Value $2.11B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, EcoR1 Capital, LLC disclosed 34 equity positions with a combined reported value of $2.11B. The filing implies a focused portfolio: its ten largest positions account for 84.4% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were ZYME ($608.49M), ANAB ($396.05M), BMY ($218.40M). By sector, the heaviest allocations are Health Care 96.5%, Financials 0.1%. Versus the prior quarter, allocation shifted toward Other (+0.8pp) and away from Health Care (-0.8pp).

Versus the prior quarter, EcoR1 Capital, LLC opened 9 new positions, trimmed 4 and fully exited 6, a turnover rate of 47.5% of positions. The portfolio's overlap with the prior quarter was 62% of names.

The largest new positions opened in Q3 2026 were BMY ($218.40M), ANRO ($56.98M), ATOS ($34.69M).

Of the 6 positions fully exited versus the prior quarter, the largest were LEGN ($23.10M), MBX ($21.45M), RLAY ($13.06M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • BMY BRISTOL-MYERS SQUIBB CO · $218.40M
  • ANRO ALTO NEUROSCIENCE INC · $56.98M
  • ATOS ATTOVIA THERAPEUTICS INC · $34.69M
  • VNDA VANDA PHARMACEUTICALS INC · $22.93M
  • GRTX ELECTRA THERAPEUTICS INC · $19.12M
  • CAPR CAPRICOR THERAPEUTICS INC · $13.04M
  • XNCR XENCOR INC · $12.47M
  • TLGYF TCGX ACQUISITION CORP · $3.13M

Fully Exited (vs previous quarter)

  • LEGN LEGEND BIOTECH CORP · prev qtr: $23.10M
  • MBX MBX BIOSCIENCES INC · prev qtr: $21.45M
  • RLAY RELAY THERAPEUTICS INC · prev qtr: $13.06M
  • PHAT PHATHOM PHARMACEUTICALS INC · prev qtr: $6.78M
  • MREO MEREO BIOPHARMA GROUP PLC · prev qtr: $317.70K
  • SRZNW SURROZEN INC · prev qtr: $115.32K

Insider Transactions (Form 4)

Latest EcoR1 Capital, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-05-07 Buy Atara Biotherapeutics, Inc. 507,407 $9.35 SEC filing
2026-04-20 Sell First Tracks Biotherapeutics, Inc. 4,705,575 $13.81 SEC filing

All insider transactions →

Fund Profile

EcoR1 Capital, LLC, based in San Francisco, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 31 positions worth $1.95B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-100470 (status: Approved), registered 2015-07-02
  • Regulatory AUM (Form ADV): $3.42B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds

Portfolio Structure

  • 31 positions · $1.95B reported value (Q2 2026)
  • Top 10 holdings = 87.7% of reported value
  • Largest position: ZYME (ZYMEWORKS INC) at 30.8%
  • Average position size: $62.85M

Sector Tilt

  • Health Care 97.3%
  • Financials 0.1%
  • (classified holdings cover 97% of value)

Quarterly Activity

  • Q2 2026: 9 new, 2 added, 5 reduced, 7 exited
  • 15 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively reallocating within Health Care, with new positions (BMY, ANRO) and significant increases (ETON, ERAS), suggesting a bullish stance on biotech/pharma innovation, while trimming some existing holdings (AKTS) due to weight adjustments. 2. Key moves: - Added: ETON (+13.8% shares), ERAS (+793.9% shares). - New: BMY (3.5M shares), ANRO (2.2M shares). - Reduced: AKTS (no share change, weight drop from 7.98% to 4.45%). 3. Portfolio structure: Highly active, concentrated in Health Care (100% of top 10), with a focus on clinical-stage biotech/pharma (high-risk, high-reward). 4. Per-holding one-liner: - ZYME: Zymeworks (biotech, unverified). - ANAB: AnaptysBio (immunotherapy, unverified). - BMY: Bristol-Myers Squibb (pharma). - ETON: Eton Pharmaceuticals (specialty pharma, unverified). - TRAX: First Tracks (biotech, unverified). - AKTS: Aktis Oncology (oncology, unverified). - CRSP: CRISPR Therapeutics (gene editing). - ANRO: Alto Neuroscience (neuropsychiatry, unverified). - LKFT: Lakefront Biotherapeutics (biotech, unverified). - ERAS: Erasca (oncology, unverified). 5. Style summary: Aggressive Health Care fund doubling down on high-growth biotech/pharma with new bets and scaled-up positions.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:21

Sector Allocation

Health Care 96.5%
Financials 0.1%
Other 3.4%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 22.97M $608.49M 28.82%
28.82%
Hold
2 7.88M $396.05M 18.76%
18.76%
Hold
3 3.50M $218.40M 10.34%
10.34%
New
4 2.47M $127.23M 6.03%
6.03%
Add
5 3.17M $112.50M 5.33%
5.33%
Hold
6 4.82M $93.93M 4.45%
4.45%
Hold
7 1.39M $76.85M 3.64%
3.64%
Hold
8 2.23M $56.98M 2.70%
2.70%
New
9 1.67M $49.43M 2.34%
2.34%
Hold
10 2.95M $43.25M 2.05%
2.05%
Add
11 3.03M $40.79M 1.93%
1.93%
Reduce
12 1.27M $35.37M 1.68%
1.68%
Hold
13 2.02M $34.69M 1.64%
1.64%
New
14 6.80M $25.17M 1.19%
1.19%
Add
15 1.15M $22.93M 1.09%
1.09%
New
16 835.00K $21.71M 1.03%
1.03%
Add
17 789.50K $21.29M 1.01%
1.01%
Hold
18 1.70M $19.12M 0.91%
0.91%
New
19 1.55M $13.19M 0.62%
0.62%
Hold
20 1.38M $13.04M 0.62%
0.62%
New
21 500.00K $12.47M 0.59%
0.59%
New
22 555.55K $12.34M 0.58%
0.58%
Hold
23 1.67M $10.47M 0.50%
0.50%
Hold
24 375.00K $8.89M 0.42%
0.42%
Add
25 235.00K $7.45M 0.35%
0.35%
Hold
26 855.63K $6.88M 0.33%
0.33%
Add
27 400.00K $6.12M 0.29%
0.29%
Hold
28 720.03K $3.79M 0.18%
0.18%
Add
29 889.61K $3.65M 0.17%
0.17%
Reduce
30 250.00K $3.13M 0.15%
0.15%
New
31 679.72K $2.83M 0.13%
0.13%
Reduce
32 200.00K $2.12M 0.10%
0.10%
Hold
33 64.30K $862.95K 0.04%
0.04%
New
34 100 $7.09K 0.00%
0.00%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 80% R 80% F1 80% (modelled on 2026-Q1; 8/10 hit)

Low-confidence forecast This fund replaces about 26% of its Top-10 each quarter and backtests at F1 73% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 73% · recall 73% · F1 73% · avg rank error 2.3 · Top-10 turnover 26%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% APLS · MRTX · PRTA · ARVN · LKFT · ACAD · ANAB · TNGX · JAZZ · ZYME APLS · PRTA · ARVN · SRPT · CRNX · LKFT · ANAB · ZYME · JAZZ · XNCR
2024-Q2 70% 70% 70% APLS · PRTA · ARVN · SRPT · CRNX · LKFT · ANAB · ZYME · JAZZ · XNCR APLS · PRTA · SRPT · ANAB · CRNX · ARVN · MORF · LKFT · KURA · TNGX
2024-Q3 70% 70% 70% APLS · SRPT · PRTA · CRNX · MORF · ANAB · ARVN · LKFT · KURA · TNGX APLS · ANAB · CRNX · PRTA · JAZZ · ZYME · ARVN · KURA · XNCR · TNGX
2024-Q4 80% 80% 80% APLS · ANAB · CRNX · JAZZ · PRTA · ZYME · ARVN · KURA · XNCR · TNGX APLS · ZYME · CRNX · JAZZ · PRTA · XNCR · PFE · ARVN · ANAB · SRPT
2025-Q1 80% 80% 80% APLS · JAZZ · ZYME · CRNX · PRTA · XNCR · PFE · ARVN · ANAB · SRPT APLS · JAZZ · ZYME · ANAB · CRNX · PRTA · SRPT · XNCR · CRSP · JANX
2025-Q2 70% 70% 70% APLS · JAZZ · ZYME · ANAB · CRNX · PRTA · SRPT · XNCR · CRSP · JANX ZYME · APLS · JAZZ · ANAB · CRNX · ITOS · CRSP · TNGX · XNCR · IMNM
2025-Q3 80% 80% 80% ZYME · APLS · JAZZ · ANAB · CRNX · ITOS · CRSP · TNGX · XNCR · IMNM ZYME · ANAB · QURE · JAZZ · CRNX · CRSP · TNGX · ORIC · APLS · XNCR
2025-Q4 60% 60% 60% ZYME · QURE · ANAB · JAZZ · CRNX · ORIC · CRSP · TNGX · XNCR · APLS ZYME · ANAB · JAZZ · CRNX · CNTA · CRSP · MBX · IMNM · ORIC · LKFT
2026-Q1 70% 70% 70% ZYME · ANAB · JAZZ · CRNX · CNTA · MBX · CRSP · ORIC · IMNM · LKFT ZYME · ANAB · JAZZ · CRNX · AKTS · ORIC · CGON · CRSP · ETON · LKFT
2026-Q2 ★ 80% 80% 80% ZYME · ANAB · JAZZ · CRNX · AKTS · ORIC · CGON · CRSP · ETON · LKFT ZYME · ANAB · AKTS · ETON · CRSP · ORIC · TRAX · LKFT · NGNE · CGON

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-13. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-13 Trading days32 Holdings5 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-13, and will update as prices arrive.

Portfolio return-5.28%Buy & hold
QQQ synthetic benchmark-13.72%Liquidity weighted
Excess return+8.44%vs benchmark
Barra annualised vol30.4%Model estimate
Realised vol25.2%Annualised in window
Weighted beta0.72Raw exposure
Factor / specific risk41% / 59%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-13EcoR1 Capital, LLCQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-5.28%Disclosed long book
QQQ synthetic benchmark-13.72%Liquidity-weighted constituents
Model universe, equal weight+0.30%Opportunity-cost reference
Excess return+8.44%Portfolio − benchmark
Arithmetic return sum-5.03%Difference vs compounded is the cross term
Weighted raw beta0.72Weighted holding betas
Realised volatility (annualised)25.17%Daily returns in window
Barra model volatility (annualised)30.41%Factor + specific
Factor share of variance40.9%Barra factors
Specific share of variance59.1%Stock residuals
Reported value$343.8M13F long US equity

2. Return attribution

The -5.03% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -1.09% -21.7%
Momentum & Growth 3 -2.16% -43.0%
Volatility & Tail Risk 7 -1.13% -22.5%
Industry 12 +8.12% 161.5%
Specific 1 -8.77% -174.3%
Return attribution (style + industry, %)-8.8-4.4+0.0+4.4+8.8Leverage (Downside Vol)+0.25Short-term Reversal+0.47Non-linear Size+0.59Beta-0.70Growth-0.83Size+0.98Mid Cap-1.08Max Drawdown-1.08Historical Volatility+1.28Turnover-1.38Momentum-1.80Residual Volatility+1.80Kurtosis-2.81Health Care+8.12
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +1.00 +8.12% +8.12% 161.5%
Residual Volatility Style +0.68 +2.66% +1.80% 35.8%
Historical Volatility Style -0.10 -12.86% +1.28% 25.4%
Size Style -0.54 -1.83% +0.98% 19.5%
Non-linear Size Style +0.64 +0.91% +0.59% 11.7%
Short-term Reversal Style +0.59 +0.79% +0.47% 9.3%
Leverage (Downside Vol) Style -0.14 -1.82% +0.25% 5.1%
Skewness Style -0.03 -4.21% +0.13% 2.6%
Amihud Illiquidity Style +0.54 -0.40% -0.22% -4.3%
Beta Style -0.15 +4.85% -0.70% -14.0%
Growth Style -0.53 +1.57% -0.83% -16.5%
Mid Cap Style +0.64 -1.69% -1.08% -21.4%
Max Drawdown Style +0.55 -1.96% -1.08% -21.4%
Turnover Style +0.29 -4.77% -1.38% -27.4%
Momentum Style +0.54 -3.34% -1.80% -35.7%
Kurtosis Style -0.40 +6.97% -2.81% -55.8%
Specific Specific — — -8.77% -174.3%

3. Risk attribution

Annualised volatility is 30.41%; factor risk explains 40.9% of variance and specific risk 59.1%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-63.9-31.9+0.0+31.9+63.9Beta-1.51Growth-0.81Non-linear Size-0.69Residual Volatility-0.41Amihud Illiquidity+0.26Turnover+0.61Leverage (Downside Vol)+0.76Mid Cap+1.68Max Drawdown+1.91Momentum+2.00Short-term Reversal+2.66Size+2.68Health Care+31.38Specific+59.14
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 59.1% +17.98% 18.0%
Health Care Industry +1.00 31.4% +9.54% 9.5%
Size Style -0.54 2.7% +0.82% 0.8%
Short-term Reversal Style +0.59 2.7% +0.81% 0.8%
Momentum Style +0.54 2.0% +0.61% 0.6%
Max Drawdown Style +0.55 1.9% +0.58% 0.6%
Mid Cap Style +0.64 1.7% +0.51% 0.5%
Leverage (Downside Vol) Style -0.14 0.8% +0.23% 0.2%
Turnover Style +0.29 0.6% +0.19% 0.2%
Amihud Illiquidity Style +0.54 0.3% +0.08% 0.1%
Residual Volatility Style +0.68 -0.4% -0.12% -0.1%
Non-linear Size Style +0.64 -0.7% -0.21% -0.2%
Growth Style -0.53 -0.8% -0.25% -0.2%
Beta Style -0.15 -1.5% -0.46% -0.5%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-0.9-0.10.71.62.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -0.54 +2.10 -2.64
Non-linear Size +0.64 +1.68 -1.04
Mid Cap +0.64 +0.13 +0.51
Beta -0.14 +1.29 -1.44
Momentum +0.54 +0.72 -0.18
Short-term Reversal +0.59 -0.64 +1.24
Residual Volatility +0.68 -0.40 +1.08
Historical Volatility -0.10 +0.86 -0.96
Liquidity +0.04 +0.11 -0.08
Amihud Illiquidity +0.54 +1.16 -0.62
Turnover +0.29 +0.21 +0.08
Growth -0.53 +0.58 -1.11
Leverage (Downside Vol) -0.14 +0.14 -0.28
Skewness -0.03 +0.24 -0.27
Kurtosis -0.40 +0.21 -0.62
Max Drawdown +0.55 -0.08 +0.63

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -19.18% +4.32% +14.12% -14.12% +14.12%
Communication Services 0.0% 2.6% +0.00% -15.54% +0.06% +0.41% -0.41% +0.41%
Utilities 0.0% 0.8% +0.00% +11.58% -0.20% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.58% -0.24% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +5.56% -1.66% -0.49% +0.49% -0.49%
Industrials 0.0% 11.1% +0.00% +7.16% -2.27% -0.80% +0.80% -0.80%
Health Care 100.0% 1.7% -5.57% +9.16% +22.08% -0.25% -14.48% -5.73%
Total +21.99% +12.73% -27.46% +7.26%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
BMY BRISTOL-MYERS SQUIBB CO Health Care 63.52% +2.70% +1.72% New
CRSP CRISPR THERAPEUTICS AG Health Care 22.35% -23.64% -5.29% Hold
NGNE NEUROGENE INC Health Care 10.29% -13.98% -1.44% Hold
ODTX ODYSSEY THERAPEUTICS INC Health Care 3.59% -13.86% -0.50% Hold
CTNM CONTINEUM THERAPEUTICS INC Health Care 0.25% -26.53% -0.07% New
Contribution rank Symbol Sector Weight Return Contribution
1 BMY Health Care 63.52% +2.70% +1.72%
2 CTNM Health Care 0.25% -26.53% -0.07%
3 ODTX Health Care 3.59% -13.86% -0.50%
4 NGNE Health Care 10.29% -13.98% -1.44%
5 CRSP Health Care 22.35% -23.64% -5.29%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-13 (32 trading days), the reported portfolio returned -5.28%, versus -13.72% for the QQQ synthetic benchmark — an excess of +8.44%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +8.12%, Residual Volatility +1.80%, Historical Volatility +1.28%; the largest drags came from Kurtosis -2.81%, Momentum -1.80%, Turnover -1.38%. Specific (stock-level) return contributed -8.77%.
  3. Risk attribution: Barra model volatility is 30.41% annualised; factor risk explains 41% of variance and specific risk 59%. The largest factor risk sources are Health Care 31.4%, Size 2.7%, Short-term Reversal 2.7%.
  4. Style tilt: size -0.54, momentum +0.54, volatility -0.10, liquidity +0.04; the weighted raw beta is 0.72. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +21.99%, selection +12.73% and interaction -27.46%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did EcoR1 Capital, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, EcoR1 Capital, LLC reported 34 equity positions worth $2.11B in aggregate; its largest disclosed positions were ZYME ($608.49M), ANAB ($396.05M), BMY ($218.40M).

How large is EcoR1 Capital, LLC's portfolio?

EcoR1 Capital, LLC reported $2.11B of long equity holdings across 34 positions as of 2026-Q3. Top-10 holdings account for 84.4% of reported value.

What is EcoR1 Capital, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ecor1-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →